Intersect ENT, Inc. (NASDAQ:XENT) insider Lisa D. Earnhardt sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $28.37, for a total transaction of $567,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Intersect ENT, Inc. (NASDAQ XENT) traded down 0.17% during trading on Tuesday, hitting $28.65. 127,358 shares of the stock were exchanged. The stock’s market cap is $836.26 million. The firm has a 50 day moving average of $30.18 and a 200-day moving average of $26.24. Intersect ENT, Inc. has a 52-week low of $7.65 and a 52-week high of $33.25.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The company had revenue of $24.00 million for the quarter, compared to analysts’ expectations of $22.62 million. During the same quarter in the previous year, the business posted ($0.21) earnings per share. Intersect ENT’s quarterly revenue was up 24.4% on a year-over-year basis. Equities research analysts anticipate that Intersect ENT, Inc. will post ($0.61) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/17/intersect-ent-inc-xent-insider-lisa-d-earnhardt-sells-20000-shares-2.html.

A number of research firms recently weighed in on XENT. TheStreet raised shares of Intersect ENT from a “d” rating to a “c-” rating in a report on Tuesday, August 1st. Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 price target on shares of Intersect ENT and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $32.00 price target on shares of Intersect ENT in a report on Wednesday, August 2nd. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $27.70.

A number of hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in shares of Intersect ENT by 0.4% during the first quarter. Wellington Management Group LLP now owns 2,921,012 shares of the medical equipment provider’s stock valued at $50,095,000 after purchasing an additional 10,683 shares during the period. FMR LLC boosted its stake in shares of Intersect ENT by 247.7% during the second quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock valued at $41,447,000 after purchasing an additional 1,056,389 shares during the period. Vanguard Group Inc. boosted its stake in shares of Intersect ENT by 6.7% during the second quarter. Vanguard Group Inc. now owns 1,139,623 shares of the medical equipment provider’s stock valued at $31,853,000 after purchasing an additional 71,750 shares during the period. Alliancebernstein L.P. boosted its stake in shares of Intersect ENT by 2,746.9% during the second quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock valued at $26,036,000 after purchasing an additional 898,785 shares during the period. Finally, Morgan Stanley boosted its stake in shares of Intersect ENT by 4.8% during the first quarter. Morgan Stanley now owns 602,499 shares of the medical equipment provider’s stock valued at $10,333,000 after purchasing an additional 27,550 shares during the period. Institutional investors and hedge funds own 83.12% of the company’s stock.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.